Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Aflibercept vs Laser Photocoagulation in Retinopathy of Prematurity
2019-001764-29Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of aflibercept in retinopathy of prematurity (ROP) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Absence of active retinopathy of prematurity and unfavorable structural outcomes. Started Oct 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2019-001764-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001764-29.